Epithelial ovarian cancer (EOC) consists of 5 major histotypes: high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), mucinous carcinoma (MC), and low-grade serous carcinoma (LGSC). Each can have a broad spectrum of morphologic appearances, and 1 histotype can closely mimic histopathologic features more typical of another. Historically, there has been a relatively high frequency of mixed, defined by 2 or more distinct histotypes present on the basis of routine histopathologic assessment, histotype carcinoma diagnoses (3% to 11%); however, recent immunohistochemical (IHC) studies identifying histotype-specific markers and allowing more refined histotype diagnoses suggest a much lower incidence. We reviewed hematoxylin and eosinstained slides from 871 cases of EOC and found the frequency of mixed carcinomas to be 1.7% when modern diagnostic criteria are applied. Through international collaboration, we established a cohort totaling 22 mixed EOCs, consisting of 9 EC/CCC, 4 EC/LGSC, 3 HGSC/CCC, 2 CCC/MC, and 4 other combinations. We interrogated the molecular differences between the different components of each case using IHC, gene expression, and hotspot sequencing analyses. IHC data alone suggested that 9 of the 22 cases were not mixed tumors, as they presented a uniform immuno-phenotype throughout, and these cases most probably represent morphologic mimicry and variation within tumors of a single histotype. Synthesis of molecular data further reduces the incidence of mixed carcinomas. On the basis of these results, true mixed carcinomas with both morphologic and molecular support for the presence of >1 histotype within a given tumor represent <1% of EOCs.
commonly showing papillary architecture; TP53 mutation is near ubiquitous (B97%), and BRCA1/2 loss is frequent (30% to 45%, including germline and somatic alterations). 5, 6 Reflecting typical histology of the most common form of endometrial carcinomas, EC (10% of EOC) generally presents at low stage with glandular architecture and squamous differentiation. 7 PTEN, CTNNB1, PIK3CA, and ARID1A are commonly mutated in EC, and tumors frequently show immunohistochemical (IHC) positivity for progesterone receptor (PR) and trefoil factor 3 (TFF3). 2, 8 Also frequently presenting at low stage, CCC (10% of EOC) is defined by an abundance of clear cells occurring in tubulocystic, papillary, or solid architecture. 7 These generally chemoresistant tumors express HNF-1b and frequently possess mutations in PIK3CA and ARID1A. 9 MC is typically a low-grade EOC characterized by goblet cells and intracellular mucin; this is a rare histotype (2% to 4% of EOC) known to harbor Ras-pathway alterations. 7, 10 Finally, LGSC (2% of EOC) frequently presents at advanced stage and is defined by low-grade nuclear atypia and low mitotic activity. 7 LGSC-associated molecular alterations include BRAF and KRAS mutations, and standard platinum-based chemotherapy is generally considered ineffective. 7, 11, 12 Historically, all EOC histotypes were thought to arise from the ovarian surface epithelium; however, contemporary hypotheses suggest distinct sites of origin and molecular events during oncogenesis for the different histotypes. HGSCs have been shown to arise from serous tubal intraepithelial carcinomas of the fallopian tube in the majority of cases. 1, [13] [14] [15] Endometriosis is associated with both EC and CCC, and ectopic endometrial glandular epithelium is thought to be the tissue of origin. [16] [17] [18] [19] The origins of MC remain elusive. 4, 20, 21 Lastly, LGSCs are still believed to originate from the ovarian surface epithelium, although this is the subject of some debate. 3, [22] [23] [24] LGSCs appear to arise from serous borderline tumors (SBT), and these are generally accepted to be a precursor of the invasive form. Despite histologic architectural similarity between HGSC and LGSC/SBT, they are accepted to arise through mutually exclusive pathways. Considering the apparently distinct origins of EOC histotypes, tumors with mixed cell types would be anticipated to be rare.
Interobserver agreement in EOC histotype diagnosis has dramatically improved in recent years, with concordance rates rising from <60% to 85% to 92% with the integration of biomarker-assisted diagnosis in equivocal cases. 25, 26 Previously, reproducibility was particularly poor in diagnosing EOC of pure histology versus those with mixed features, 25 and the reported frequency of mixed EOC ranged from 3% to 11% between 1975 and 2006. [27] [28] [29] [30] [31] [32] [33] With modern diagnostic criteria and the use of molecular markers, it is now appreciated that ovarian carcinoma histotypes can show a spectrum of morphologic features. A corollary of this observation is that papillary architecture does not equate to serous carcinoma, glandular architecture does not equate to EC, and the presence of clear cells is not pathognomonic of CCC. Recognition of the spectrum of architectural features associated with each histotype, especially HGSC, has resulted in fewer diagnoses of mixed celltype cancer and better interobserver concordance in histotype diagnosis. [34] [35] [36] In this study, we set out to catalog the largely understudied group of mixed ovarian carcinomas, assessing whether there is a molecular basis for morphologic heterogeneity and establishing a true frequency within a large population-based cohort. Disparate regions of mixed tumors were further interrogated using molecular analyses including IHC, gene expression, and hotspot sequencing. Herein, we report mixed-type ovarian carcinomas to occur at a frequency of 1.7% after morphologic review. With further molecular analysis, this frequency drops to <1%, where the use of common IHC biomarkers generally suffices in identifying true mixed-type EOC.
MATERIALS AND METHODS

Case Selection
Review of the 871-case Ovarian Cancer in Alberta and British Columbia study (OVAL-BC) cohort of EOC was performed, and cases were diagnosed as mixed EOC when, on the basis of routine hematoxylin and eosin (H&E) stains, there were 2 or more distinct histotypes present, and each comprised at least 10% of the total tumor volume. For the purpose of this study we accepted as "mixed carcinomas" any tumor in which 1 component was carcinoma and the other borderline, as long as they were different histotypes; there were only 2 such cases in the series, and we acknowledge that some would not consider these to be true examples of mixed carcinoma, reserving that designation for cases in which both/all components of the tumor are carcinomatous. The frequency of mixed carcinoma was established using this cohort. Also included were 17 cases, initially diagnosed as mixed-type, that were referred to us from the AGO (Arbeitsgemeinschaft Gyna¨kologische Onkologie) study group. After review using modern criteria, a single case retained a diagnosis of mixed type and was included in this study (Supplemental Digital Content 1, http://links. lww.com/PAS/A291). Additional mixed-type cases from the hospitals of Vancouver Costal Health (VCH) (British Columbia), The Leeds Teaching Hospital (Leeds), and Barts Health (London) were reviewed for inclusion on a case-by-case basis ( Fig. 1 ). Formalin-fixed paraffin-embedded (FFPE) tissue was available for all cases.
Immunohistochemistry
We refined a previously described 10-marker algorithm termed COSPv2 (Calculator of ovarian carcinoma subtype prediction version 2), 37 to an 8-marker panel (p53, p16, PR, WT1, ARID1A, HNF1B, VIM, and TFF3) that distinguish between ovarian carcinoma histotypes with 90% accuracy. IHC was performed on freshly cut full sections of FFPE tissue and scored independently for the distinct regions of each mixed-type case. 8, 37 A binary scoring method was used with a cutoff of 1% for PR, and WT1, 10% for ARID1A, 50% for HNF1B, TFF3, and VIM, and 90% for p16. 37 Expression of p53 was quantified using a 3-tiered scoring system (0 = complete loss, 1 = wild type/variable expression intensity in 1% to 70% of tumor cell nuclei, 2 = overexpression/ >70% of tumor cell nuclei) and binned accordingly (score of 1 = bin of 0/normal; score of 0 or 2 = bin of 1/abnormal). 37, 38 A histotype diagnosis was independently calculated from the immunostaining results for each component of the mixed EOC, as described previously. 37, 38 Additional detail on antibodies, dilutions, and protocol can be found in Supplemental Digital Content 2 (http://links.lww.com/PAS/A292).
Macrodissection and Nucleic Acid Extraction
Nucleic acids were extracted from FFPE tissue blocks sectioned at 10 mm when a single histotype was present within a given block. When different histotypes were present on the same block, distinct regions were separated by macrodissection using the H&E slide as a guide after having been marked by an expert pathologist (C.B.G.). DNA and RNA were extracted using the Qiagen AllPrep FFPE kit, according to the manufacturers recommended protocols, with the following exceptions: deparaffinization was done using xylene, with digestion of tissue before RNA extraction for 30 minutes, and use of RBC buffer (Qiagen RNeasy FFPE kit) rather than buffer FRN.
Gene Expression
Mixed-type cases with RNA extraction yields of sufficient quantity (>400 ng) and purity (optical density 260/280, 1.7 to 2.5) were selected for expression analysis. Using a custom codeset synthesized by NanoString (Seattle, WA), the expression levels of 363 genes were quantified. 39 Five endogenous housekeeping genes (ACTB, RPL19, SDHA, PGK1, POLR1B), plus spikedin, nonhuman positive and negative controls were used to normalize and ensure assay success. RNA (400 ng) was hybridized and run on the nCounter Analysis System as described previously. 39, 40 Gene expression was analyzed using a preselected gene panel enriched for genes that were found to be differentially expressed between histologic types of ovarian cancer. As this was not a genomewide profile, it partially restricted the scope of statistical analysis of these data. A qualitative analysis using multidimensional scaling (MDS) was used, as this provides a means of visualizing the degree of similarity between cases in our data sets. Generally speaking, the closer 2 points are, the more similar are their gene expression profiles. MDS plots were used to assess the extent of gene expression similarity between components of a mixed tumor, and whether these components fall within a highlighted region of the plot typically populated by EOC of corresponding "pure-type." These "pure-type" EOCs were sourced from the OVCARE tumor bank (Vancouver, Canada) and included 19 CCCs, 12 ECs, 95 HGSCs, 12 LGSCs, and 10 MCs. All "pure-type" tumors had high cellularity, an immuno-profile characteristic of their representative histotype (chosen from a subset of samples described in Kalloger et al 8 ) , and, on review, did not exhibit morphologic characteristics that suggested overlap with another histologic type.
Mutation Analysis
Components from 11 mixed-type tumors were sequenced independently using the IonTorrent platform. Amplicon libraries were prepared and barcoded using the Cancer Hotspot Panel v2 primer pool and IonXpress barcode adapter kit. Libraries were quantified using Agilent High Sensitivity DNA chips, diluted to 20 pM, and pooled together. Pooled libraries were clonally amplified onto IonSphere particles using the OneTouch2 system and loaded onto Ion 316 or 318 chips depending on the number of cases pooled together (2 cases-316, 3 cases-318). The Ion Torrent Variant Caller (version 3.6) was used to detect variants with hg19 as a reference genome.
Post-sequencing quality control steps were implemented to account for procedural and nucleic acid integrity limitations involved in sequencing DNA extracted from FFPE tissue. Initial screening limited reported variants to those observed at a minimum 5% allelic frequency and 10Â coverage. Normal tissue was unavailable for sequencing, so our analysis was restricted to include only nonsynonymous alterations occurring in hotspot regions that have been reported in a mutation database (catalogue of somatic mutations in cancer,
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Review Using Modern Diagnostic Criteria FIGURE 1. Overview of mixed cell type cohort and experimental process including the 871-case fully reviewed OVAL-BC cohort and a small collection of referred cases from collaborating institutions. Our experimental design began with morphologic assessment, followed by IHC profiling using a standardized IHC panel, gene expression profiling on a limited set of histotype-specific genes, and mutational analysis of common cancer-associated genes.
COSMIC 41 ). Insertions or deletions resulting in a truncated protein were also included in our data set.
RESULTS
Mixed Cell-type Carcinomas in a Populationbased Series
After review of the 871-case OVAL-BC cohort of EOC, we identified 856 cases of so-called pure-type EOC: 578 (66%) HGSCs, 111 (13%) ECs, 97 (11%) CCCs, 44 (5%) MCs, 26 (3%) LGSCs, and 15 with mixed histology. As OVAL-BC is a population-based cohort with representative proportions of the major histotypes, the overall frequency of mixed-type EOC can be approximated at 1.7% when diagnosed based solely on morphologic criteria. Among these mixed EOCs, EC/CCC mixes were most common (6 cases), followed by EC/LGSC (4 cases) and CCC/MC (2 cases), with other mixes comprising the remainder of the observed mixed tumors (1 case each of MC/SBT, MC/borderline Brenner, and MC/HGSC).
To expand our series for molecular analysis, additional mixed EOC cases were acquired: 17 from the AGO study group (see Table, Supplemental Digital Content 1, http://links.lww.com/PAS/A291, for initial and review diagnosis of AGO study group cases) and 6 cases from collaborating centers (4 from hospitals of VCH, 1 from Barts Health NHS Trust, and 1 from The Leeds Teaching Hospital NHS Trust). After review of H&E-stained slides, we retained all cases from VCH, Barts Health, and The Leeds Teaching Hospital and 1 case from the AGO study group (Fig. 1 ). Our final cohort of mixed-type carcinomas comprised 9 EC/CCC, 4 EC/LGSC, 3 HGSC/CCC, 2 MC/CCC, and 4 additional cases that were grouped as "other" mixes (Table 1) .
IHC Analysis
IHC profiling of mixed-type tumors identified 9 cases in which components were predicted to be the same histotype; that is, the immunoprofile of morphologically distinct components in these "mixed" tumors was indistinguishable ( Table 2 ). For the 13 remaining cases, the immunoprofiles of the different components were distinct, and for 23 of 26 (88%) individual elements, the predicted histotype, on the basis of the immunoprofile, corresponded to what was predicted on the basis of H&E morphologic examinations, a level of agreement with morphologic assessment similar to what has been observed previously. 42 Figure 2 shows a selection of IHC stains for MX11, a CCC and EC admixed case with distinct immunoprofiles. The EC/LGSC mixed case, MX4, was predicted to be a mix of EC and CCC based on IHC profiling. MX25, an admixture of MC and borderline Brenner tumor, presented a unique case, as Brenner tumors are not included at all in the IHC prediction algorithm. Although the immuno-phenotypes differed between components, this was solely the result of expression of TFF3, with no additional molecular information available.
Gene Expression
Gene expression results were obtained for 21/22 mixed EOC cases (all but MX25; insufficient RNA was extracted). Similar expression patterns, represented by cosegregation of mixed components within a cloud, or region, of "pure-type" EOC on the MDS plot were observable in all 9 cases in which components had indistinguishable immunoprofiles ( Fig. 3 EC and CCC admixed cases with distinct immunoprofiles for the 2 components had gene expression results in agreement with the immunoprofile; that is, those components showing CCC morphology fell within their corresponding cloud of "pure" CCC type, with the same holding true for the EC component. The sixth case (MX12) was also concordant, in that the components separated; however, the CCC component also showed some distance from a pure CCC type (Fig. 3C) . Similar trends were observed for 2 HGSC/CCC cases (MX27 and MX28), and 1 EC/LGSC mixed EOC (MX1). Although distinct components of MX8 (MC/CCC) did not lie within either cluster of pure-type EOC (Fig. 3B ), there is a large amount of separation between the components, indicating dissimilarity in the expression profiles of the 2 regions. Thus the results of gene expression analysis were concordant with immunophenotypic characterization. When considering both IHC and gene expression data, 9/ 22 (41%) cases did not show molecular evidence for the 
Mutation Analysis
Finally, cancer hotspot sequencing analysis was performed for 11 available cases of mixed EOC ( Table 3 ). The 11 cases were selected such that at least 1 representative of each of the major groups (outlined in Table 1 ) was sequenced. In 3 cases, sequencing was concordant with IHC and gene expression results of molecularly homogenous tumors with morphologic heterogeneity showing the characteristic TP53 (HGSC; MX5, MX21) and PI3KCA (CCC; MX7) mutations at moderately equal proportions throughout the tumors.
Identical mutations were observed within the distinct regions of 2 EC and CCC admixed cases: MX11 contains a PIK3CA p.E542K, whereas MX12 harbors PTEN (p.Y176Lfs*4) and TP53 (p.R175H) mutations. Found exclusively within the EC region of the tumor, CTNNB1 p.S33C and TP53 p.A161T mutations were found in MX2 and MX3, respectively. TP53 mutations were also found in all 3 mixed HGSC/CCC cases, presenting in both regions of MX28; however, only the HGSC region of MX27 had the observed TP53 p.R175H alteration. Both sequenced cases of MC/CCC mixed EOC harbored identical mutations in their distinct components: PIK3CA p.H1047L in MX7 and KRAS p.G12D in MX8.
DISCUSSION
In summary, 9 of 22 (41%) tumors that were mixed on the basis of morphologic assessment were pure histotypes on the basis of molecular studies, whereas 12 of 22 (55%) were mixed on the basis of both morphologic and molecular (IHC and genomic) analyses (Table 4) ; one case was inconclusive (MX25; Brenner/MC). Of the 12 "true" mixed tumors, molecular results confirmed the morphologic impression of histotype in 92% (11/12) of cases. In the 1 discordant case and the 1 ambiguous case, morphologic assessment suggested LGSC and Brenner tumor components, respectively, both of which were interpreted as CCC on the basis of molecular analysis. In the latter cases, the discordant component was an uncommon histotype, for which the molecular characteristics are not well defined, and on the basis of review neither showed characteristic morphologic features of CCC. Overall, this suggests that these are best considered examples of molecular misclassification and, in the context of our study, were more accurately classified on the basis of morphologic assessment. Historically, mixed-type EOC accounted for up to 11% of cases. [27] [28] [29] [30] [31] [32] [33] Even as recently as 2010 it was stated that "Careful study of [ovarian] tumors often reveals two or even three or more cell types" 43 ; however, the criteria for diagnosis of EOC histotypes have evolved, 44 and recent studies suggest a much lower frequency. Currently, fewer mixed EOC diagnoses are being made; however, no concrete figure exists for the frequency of mixed-type EOC on the basis of current diagnostic criteria, and few studies examining the molecular alterations of these admixtures have been published. To address this, we conducted a population-based review, establishing a frequency of 1.7% for EOC of apparent mixed histology on the basis of routine histopathologic assessment, and suggest an even lower figure (8/871 OVAL-BC cohort; 0.9%) on the basis of molecular analysis. Generally, the cases of EOC with mixed morphologic features studied herein fall within 1 of 2 main groupings: (1) tumors with uniform molecular features throughout, consistent with their being a single histotype, but displaying morphologic plasticity within distinct regions, and (2) tumors in which the observed heterogeneity represents a more complete divergence of molecular and morphologic features stemming from a common ancestral clone. Examples from the former category can be identified on the basis of similar IHC and gene expression profiles in the morphologically distinct regions of these tumors, and include cases of MX3, MX5, and MX21. Identical mutations occurring within distinct regions of MX21 and MX5 further support this conclusion. Interestingly, a TP53 p.A161T mutation was observed to occur solely in the EC region of MX3. This is presumably a new mutation acquired during tumor progression, occurring within a subpopulation of the tumor and potentially driving the divergence of morphology.
Microscopic heterogeneity observed in the morphology of mixed EOC falling within the second of the 2 categories extends to the molecular level, wherein distinct IHC and gene expression profiles exist for the disparate regions. However, a unifying mutation exists in nearly every case: for example, a KRAS p.G12V mutation in both EC and LGSC regions of MX4, a TP53 mutation in the CCC and HGSC regions of MX28, and identical KRAS p.G12D mutations in the CCC and MC regions of MX8. In addition, most of the cases that fall within this category are admixed CCC and EC, 2 histotypes that are largely accepted to arise from the same cell of origin, that is, glandular epithelial cells of endometriosis. 18, 19, [45] [46] [47] [48] The mutational data, where informative, indicate that, in such cases, the morphologically and molecularly distinct regions have arisen from the same initiation event. The sequencing panel used in this study is limited to hotspot regions of 50 genes and, in cases such as MX2 with only a single CTNNB1 mutation in the EC component and no detectable mutations in the CCC, many ancestral mutations, such as ARID1A, 48 may have been missed.
Previous studies identified the presence of cells with clear cytoplasm within serous carcinoma as representing regions of morphologic plasticity within a pure serous tumor. 26, 34 One such example exists in our cohort (MX21); however, the remaining 2 HGSC/CCC cases (MX27 and MX28) have remarkable disparity in IHC staining patterns. The distinct regions of MX27 exhibit classical IHC profiles of pure-type HGSC and CCC, and a TP53 mutation was found exclusively in the HGSC region (see Figure, Supplemental Digital Content 5, http://links.lww.com/PAS/ A297, which shows distinct IHC staining for MX27). From our analysis, it is not possible to determine whether this case has arisen as the result of a distant common precursor that has undergone drastic subclonal divergence, or whether it is a true mixed, or "collision" tumor. In MX28, however, a TP53 mutation was found within both regions suggesting that this unusual tumor is likely to have arisen from a common precursor.
Molecular analysis of admixed EC and LGSC shows different results for each case examined. On the basis of the molecular analyses, both MX6 and MX5 can be considered tumors of uniform histotype that display morphologic plasticity within distinct regions. IHC and gene expression results suggest that MX1 and MX4 are true mixed tumors.
Epithelial ovarian tumors with mixed-type histology are uncommon, and bona fide mixed EOCs in which there is both morphologic and molecular evidence of 2, or more, histotypes account for approximately 1% of cases. CCC/ EC admixtures are most commonly encountered, and this is likely in part related to their common ancestral lineage. In clinical practice, selective use of IHC can distinguish between true mixed EOC, and pure EOC with morphologic variation, mimicking different histotypes. Although 1 immunomarker may be sufficient to determine the relatedness between 2 regions of a mixed EOC, use of an IHC panel is ideal in these cases. Some of the immunostaining analyses in this study were performed using polyclonal purified antibodies (specifically those for HNF1B and ARID1A). Although the same reagent lot was used throughout this study, and no variation in staining was observed across our controls, the potential for batch-to-batch variability of such preparation may be problematic for routine clinical use. Finally, the clinical significance of true mixed histotypes is unclear, and more cases with follow-up will be needed to know whether their natural history is comparable to that of EOC of pure histotype.
